Abstract
Nanoparticles in cancer therapy have garnered significant attention in the past few decades. Cancer immunotherapy, which is aptly called “the new-generation cancer therapy,” is slowly making remarkable strides in the improvement of patient outcome and longevity. Taken together, nanoparticles in immune therapy have the potential to offer advantages of both nanoparticles and immune therapy on a single platform.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Liu CY et al (2013) M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab Investig 93:844–854
Zanganeh S et al (2016) Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol 11:986–994
Xie Z et al (2017) Immune cell-mediated biodegradable theranostic nanoparticles for melanoma targeting and drug delivery. Small 13:1–10
Alsaab HO et al (2017) PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 8:1–15
Sau S et al (2018) Multifunctional nanoparticles for cancer immunotherapy: a groundbreaking approach for reprogramming malfunctioned tumor environment. J Control Release 274:24–34
Bhise K et al (2018) Combination of vancomycin and cefazolin lipid nanoparticles for overcoming antibiotic resistance of MRSA. Materials (Basel) 11(7):pii: E1245
Bhise K, Kashaw SK, Sau S, Iyer AK (2017) Nanostructured lipid carriers employing polyphenols as promising anticancer agents: quality by design (QbD) approach. Int J Pharm 526:506–515
Bhise K et al (2017) Nanomedicine for cancer diagnosis and therapy: advancement, success and structure-activity relationship. Ther Deliv 8:1003–1018
Sau S et al (2018) Abstract 4660: tumor multicomponent targeting nanoparticle library for personalized cancer therapy and imaging. Cancer Res 78:4660–4660
Alsaab HO et al (2018) Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials 183:280–294
Yang G et al (2017) Hollow MnO2as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses. Nat Commun 8:902. https://doi.org/10.1038/s41467-017-01050-0
Huang P et al (2011) Biomaterials folic acid-conjugated silica-modified gold nanorods for X-ray/CT imaging-guided dual-mode radiation and photo-thermal therapy. Biomaterials 32:9796–9809
Zampell JC et al (2012) CD4+ cells regulate fibrosis and lymphangiogenesis in response to lymphatic fluid stasis. PLoS One 7:e49940. https://doi.org/10.1371/journal.pone.0049940
Acknowledgments
The authors acknowledge partial support for this work by Wayne State University startup funding. A.K.I. acknowledges a grant from the Department of Defense (DoD) CDMRP KCRP Idea Development Award (#W81XWH-18-1-0471) as an Early Career Investigator. S.S. and A.K.I. acknowledge a grant support from the Burroughs Wellcome Trust. K.B. acknowledges Thomas C. Rumble University Graduate Fellowship and Graduate Research Fellowship from the Wayne State University. R.A. acknowledges the scholarship support from College of Pharmacy at Taif University and Saudi Arabian Cultural Mission (SACM).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Bhise, K., Sau, S., Alzhrani, R., Iyer, A.K. (2020). Nanoparticles for Immune Cell Reprogramming and Reengineering of Tumor Microenvironment. In: Katz, S., Rabinovich, P. (eds) Cell Reprogramming for Immunotherapy. Methods in Molecular Biology, vol 2097. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0203-4_13
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0203-4_13
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0202-7
Online ISBN: 978-1-0716-0203-4
eBook Packages: Springer Protocols